Xylem said revenue for 2024 was $8,562 million, an increase of $1,198 million (16.3%) compared to 2023 revenue of $7,364 million. At constant currency, the increase consisted of acquisition revenue of $786 million and organic revenue growth of $424 million.

10-KAnnual reportFiled Mar 3, 2025Period of report Dec 31, 2024Summary published (UTC) Oct 10, 2026

Key points

AI summary

Xylem said revenue for 2024 was $8,562 million, an increase of $1,198 million (16.3%) compared to 2023 revenue of $7,364 million. At constant currency, the increase consisted of acquisition revenue of $786 million and organic revenue growth of $424 million.
The company said operating income for 2024 was $1,009 million (operating margin of 11.8%), an increase of $357 million compared to prior-year operating income of $652 million (8.9%). Net income was $890 million, an increase of $281 million compared to prior-year net income of $609 million.
Xylem cited increased operating income of $357 million and a non-recurring gain on remeasurement of its previously held equity interest in Idrica of $152 million as factors in the net income increase. It said the growth was partially offset by increased income tax expense of $171 million and increased loss on sale of businesses of $45 million.
The company said net cash from operating activities for 2024 was $1,263 million, an increase of $426 million compared to 2023 net cash from operating activities of $837 million. It also said available liquidity totaled approximately $2.1 billion, consisting of cash of $1.1 billion and available credit facilities of $1 billion.

Key figures

Fiscal year ended December 31, 2024

Revenue: $8.6B
Operating income: $1.0B
Net income: $890M
EPS: $3.65
Gross profit: $3.2B
Operating cash flow: $1.3B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

2024 revenue $8,562 million, including acquisition revenue of $786 million

Xylem said revenue for 2024 was $8,562 million, an increase of $1,198 million (16.3%) compared to 2023 revenue of $7,364 million. At constant currency, the increase consisted of acquisition revenue of $786 million and organic revenue growth of $424 million.

Source · Based on the MD&A text of the filing

Operating income $1,009 million, net income $890 million

The company said operating income for 2024 was $1,009 million (operating margin of 11.8%), an increase of $357 million compared to prior-year operating income of $652 million (8.9%). Net income was $890 million, an increase of $281 million compared to prior-year net income of $609 million.

Source · Based on the MD&A text of the filing

Gain on remeasurement of Idrica equity interest $152 million and increased income tax expense

Xylem cited increased operating income of $357 million and a non-recurring gain on remeasurement of its previously held equity interest in Idrica of $152 million as factors in the net income increase. It said the growth was partially offset by increased income tax expense of $171 million and increased loss on sale of businesses of $45 million.

Source · Based on the MD&A text of the filing

Net cash from operating activities $1,263 million, available liquidity approximately $2.1 billion

The company said net cash from operating activities for 2024 was $1,263 million, an increase of $426 million compared to 2023 net cash from operating activities of $837 million. It also said available liquidity totaled approximately $2.1 billion, consisting of cash of $1.1 billion and available credit facilities of $1 billion.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗